LONDON – Actelion Pharmaceuticals Ltd. is paying €10 million (US$12.9 million) in cash for the option to acquire Trophos SA for up to €195 million cash once it gets Phase III data on olesoxime, a treatment for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. (BioWorld International)

In a quid pro quo with erstwhile partner Sanofi Pasteur, Crucell NV regained control over its cell-culture-based influenza vaccine program by agreeing not to exercise its rights, under a change-of-control clause, to terminate a contract with Sanofi Pasteur subsidiary Shantha Biotechnics Ltd. on the production of a pediatric vaccine against Haemophilus influenzae B. (BioWorld International)